Atrophin-1 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">atrophin-1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATROPHIN-1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>atrophin-1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ATROPHIN-1" target="_blank">Search UniProt</a></td>
</tr>
</table>
Introduction
Atrophin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Atrophin-1 is a predominantly nuclear protein encoded by [ATN1](/proteins/atn1-protein) and is best known as the disease protein in [Dentatorubral-Pallidoluysian Atrophy (DRPLA)](/diseases/drpla).[@koide1994][@dsouza2023] DRPLA is one of the polyglutamine neurodegenerative disorders, and the pathogenic event is expansion of a CAG repeat in ATN1 that lengthens the polyglutamine tract of atrophin-1.[@koide1994][@sato2012] This biochemical change increases the propensity of the protein to misfold and form intranuclear aggregates that correlate with neuronal dysfunction and progressive neurodegeneration.[@dsouza2023][@yamada1999] [@dsouza2023]
Structure and Domain Organization
...Atrophin-1 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">atrophin-1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATROPHIN-1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>atrophin-1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ATROPHIN-1" target="_blank">Search UniProt</a></td>
</tr>
</table>
Introduction
Atrophin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Atrophin-1 is a predominantly nuclear protein encoded by [ATN1](/proteins/atn1-protein) and is best known as the disease protein in [Dentatorubral-Pallidoluysian Atrophy (DRPLA)](/diseases/drpla).[@koide1994][@dsouza2023] DRPLA is one of the polyglutamine neurodegenerative disorders, and the pathogenic event is expansion of a CAG repeat in ATN1 that lengthens the polyglutamine tract of atrophin-1.[@koide1994][@sato2012] This biochemical change increases the propensity of the protein to misfold and form intranuclear aggregates that correlate with neuronal dysfunction and progressive neurodegeneration.[@dsouza2023][@yamada1999] [@dsouza2023]
Structure and Domain Organization
Atrophin-1 is a large multi-domain protein with a polyglutamine tract near the N-terminus and regions that mediate nuclear localization and partner interactions involved in transcriptional regulation.[@dsouza2023][@nagafuchi1994] In disease alleles, expansion of the polyglutamine segment changes biophysical behavior, promoting abnormal conformations and aggregation-prone intermediates, especially under neuronal stress conditions.[@dsouza2023][@yamada1999] [@sato2012]
Although high-resolution full-length human atrophin-1 structures remain limited, convergent data from domain-level studies and cellular models support a model in which repeat expansion perturbs dynamic interactions with transcriptional machinery and chromatin-associated factors.[@dsouza2023][@yanagisawa] [@yamada1999]
Normal Cellular Function
Physiologically, atrophin-1 acts as a transcriptional coregulatory protein, contributing to repression/activation balance across neuronal gene networks important for development, synaptic stability, and stress adaptation.[@dsouza2023][@yanagisawa] This role is consistent with the observation that distinct ATN1 variant classes can yield very different neurologic phenotypes, from developmental disorders to age-dependent neurodegeneration.[@whitton][@palmer2019] [@nagafuchi1994]
Atrophin-1 function is tightly linked to protein homeostasis pathways. Cellular handling of wild-type and mutant forms intersects with [Autophagy](/entities/autophagy) and the [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system), and imbalance in these pathways may amplify toxicity in vulnerable neuronal populations.[@dsouza2023][@yamada1999] [@yanagisawa]
Role in DRPLA Pathogenesis
In DRPLA, mutant atrophin-1 accumulates in intranuclear inclusions and alters transcriptional programs in affected circuits spanning [Cerebellum](/brain-regions/cerebellum), [Basal Ganglia](/brain-regions/basal-ganglia), [Thalamus](/brain-regions/thalamus), and [Brainstem](/brain-regions/brainstem).[@sato2012][@yamada1999] Pathogenic mechanisms include toxic gain of function, altered protein interaction networks, and chronic cellular stress that may secondarily engage [neuroinflammation](/mechanisms/neuroinflammation).[@dsouza2023][@yamada1999] [@whitton]
Clinically, repeat length in atrophin-1 predicts major features of disease trajectory. Longer repeats are associated with earlier onset and severe juvenile phenotypes, while shorter pathogenic expansions are often seen in adult-onset cases with relatively slower progression.[@sato2012][@niewiadomskacimicka2018] These relationships support use of repeat sizing as both a diagnostic and prognostic biomarker. [@palmer2019]
Relationship to Other Polyglutamine Disorders
Mutant atrophin-1 shares core biology with proteins involved in [Huntington's Disease](/mechanisms/huntington-pathway) and multiple [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia) subtypes: CAG-repeat expansion, proteostasis stress, and circuit-level selective vulnerability.[@dsouza2023][@paulson2012] The overlap enables cross-disease therapeutic hypothesis testing in fields such as antisense/siRNA suppression, aggregation modulation, and network-level biomarker development. [@niewiadomskacimicka2018]
Therapeutic Targeting
There is no approved disease-modifying therapy directly targeting atrophin-1. Current management is symptomatic, while translational work is focused on reducing mutant protein burden and interrupting toxic downstream pathways.[@dsouza2023][@sato2012] Potential strategies include allele-selective nucleic-acid therapies, gene-editing concepts, and combination approaches that couple mutant-protein lowering with support of proteostasis and anti-inflammatory pathways.[@dsouza2023][@yamada1999] [@paulson2012]
Brain Atlas Resources
- Allen Human Brain Atlas: [Atrophin-1 Protein expression search](https://human.brain-map.org/microarray/search/show?search_term=Atrophin-1+Protein)
- Allen Mouse Brain Atlas: [Atrophin-1 Protein search](https://mouse.brain-map.org/search/index.html?query=Atrophin-1+Protein)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [Atrophin-1 Protein developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Atrophin-1+Protein)
Background
The study of Atrophin 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@genes]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@proteins]
Additional evidence sources: [@diseases] [@ncbi] [@uniprot]
External Links
- [DRPLA Foundation](https://www.drpla.org)
- [National Institute of Neurological Disorders and Stroke](https://www.ninds.nih.gov)
- Dentatorubral-Pallidoluysian Atrophy (DRPLA)
- Ataxin Proteins
- [Huntington's Disease](/diseases/huntingtons-disease)
- Frontotemporal Dementia (FTD)
- Polyglutamine Diseases
- [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration) [GeneReviews: DRPLA](https://www.ncbi.nlm.nih.gov/books/NBK1114/)
- [OMIM: Atrophin-1](https://www.omim.org/entry/607407)
- [UniProt: ATN1](https://www.uniprot.org/uniprotkb/P51800/entry)
References
[Koide et al., Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/8136840/)
[Unknown, D'Souza and La Spada, Atrophin-1 Function and Dysfunction in Dentatorubral-Pallidoluysian Atrophy (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36809552/)
[Sato et al., Dentatorubral-pallidoluysian atrophy (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/21827919/)
[Yamada et al., Molecular pathology of dentatorubral-pallidoluysian atrophy (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10434307/)
[Nagafuchi et al., Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/8136826/)
[Yanagisawa et al., Transcriptional repression by atrophin proteins and biological significance (review) (n.d.)](https://doi.org/10.1016/S1044-7431(99)
Whitton et al., ATN1-Related Neurodevelopmental Disorder (GeneReviews) (n.d.)
[Palmer et al., De Novo Variants Disrupting the HX Repeat Motif of ATN1 Cause a Recognizable Non-Progressive Neurocognitive Syndrome (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30704886/)
[Unknown, Niewiadomska-Cimicka and Trottier, Dentatorubral-pallidoluysian atrophy: an update (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30410817/)
[Unknown, Paulson, The spinocerebellar ataxias (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22149030/)
Unknown, - [Genes Index](/genes) (n.d.)
Unknown, - [Proteins Index](/proteins) (n.d.)
Unknown, - [Diseases Index](/diseases)## External Links (n.d.)
-, NCBI Gene (n.d.)
-, UniProt (n.d.)